



chain nodes :
15 19
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds :
7-15 8-19 11-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-14 11-12
12-13 13-14
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-15 8-9 8-19 10-11
10-14 11-12 11-15 12-13 13-14

G1:C,N

G2:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 19:Atom

```
=> d his

     (FILE 'HOME' ENTERED AT 10:11:13 ON 14 MAR 2000)

     FILE 'REGISTRY' ENTERED AT 10:11:20 ON 14 MAR 2000
L1             STRUCTURE UPLOADED
L2             QUE L1
L3           50 S L2
L4            1 S INDOLINE/CN

     FILE 'STNGUIDE' ENTERED AT 10:16:19 ON 14 MAR 2000

     FILE 'REGISTRY' ENTERED AT 10:18:10 ON 14 MAR 2000

     FILE 'STNGUIDE' ENTERED AT 10:18:11 ON 14 MAR 2000

     FILE 'REGISTRY' ENTERED AT 10:18:36 ON 14 MAR 2000
L5         41018 S NC4-NC5/ES
L6             1 S L2  SUB=L5 SAM
L7          1102 S L2 SSS FUL
L8             5 S L7 AND L5

     FILE 'CAPLUS' ENTERED AT 10:25:47 ON 14 MAR 2000
L9             2 S L8
L10          202 S L7

=> d l2

L2 HAS NO ANSWERS
L1              STR
```




```
G1 C,N
G2 O,S,N


Structure attributes must be viewed using STN Express query preparation.
L2              QUE  ABB=ON  PLU=ON  L1


=> d bib abs hitstr l9 1-2


L9   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2000 ACS
AN   2000:117197  CAPLUS
TI   3-Methylidenyl-2-indolinone modulators of protein kinase
```

IN Tang, Peng Cho; Sun, Li; Miller, Todd Anthony; Liang, Congxin; Tran, Ngoc My; Nguyen, Anh Thi; Nematalla, Asaad
PA Sugen, Inc., USA
SO PCT Int. Appl., 347 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000008202	A2	20000217	WO 1999-US17845	19990804

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-129256 19980804
US 1998-95470 19980805
US 1998-102178 19980928
US 1999-116107 19990115
GI



I



II

AB The title compds. (I) [wherein A = C or N; Q = substituted Ph, pyrrolyl, or indolyl; R0 = H, alkyl, C(O)R19, or C(O)OR19; R1 = H, (un)substituted alkyl, alkoxy, halo, aryl, (CH2)nOC(O)R19, or C(O)NR19; R2 = H, (cyclo)alkyl, (hetero)aryl, heteroalicyclic, trihalomethyl, alkoxy, halo, sulfamido, C(O)OR19, C(O)R19, NHC(O)OR19, (un)substituted amino, etc.; R3 = H, alkyl, trihalomethyl, alkoxy, aryl(oxy), heteroaryl, heteroalicyclic,

OH, halo, sulfamido, C(O)R19, (un)substituted amino, etc.; R4 = H, alkyl, alkoxy, or halo; R19 = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl; n = 1-4] were prepd. as modulators of the activity of receptor tyrosine kinases (RTKs), non-receptor protein tyrosine kinases (CTKs), and serine/threonine protein kinases (STKs). Examples include over 200 syntheses and data from seventeen bioassays. For instance, II was prepd. by a 3-step sequence involving: (1) cyclization and redn. of 2,4-dinitrophenylacetic acid with SnCl2.2H2O in EtOH to form 6-amino-2-oxindole, (2) amidation with AcCl in CH2Cl2, and (3) condensation of the amide with 3,5-diisopropyl-4-methoxybenzaldehyde. II was tested for HER-2 kinase activity (IC50 = 6.4 .mu.M), cellular proliferation activity as measured by the incorporation of bromodeoxyuridine (BrdU) driven by HER-2 (IC50 = 9.1 .mu.M) or EGF (IC50 = 11 .mu.M), and antitumor activity as measured by growth of SKOV3 ovarian carcinoma cells (IC50 = 2.6 .mu.M) or A431 human epidermoid carcinoma cells (IC50 = 2.2 .mu.M). The invention compds. are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer, diabetes, hepatic cirrhosis, cardiovascular disease, and immunol. disease.

IT **258831-03-7P**

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of 3-methylidenyl-2-indolinones as protein kinase modulators for the prevention and treatment of cancer, diabetes, hepatic cirrhosis, cardiovascular disease, and immunol. disease)

RN 258831-03-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS

AN 1999:297422 CAPLUS

DN 130:325139

TI Preparation of arylmethylideneazaoxindoles as protein kinase inhibitors.

IN Cheung, Mui; Glennon, Kimberly Caroline; Lackey, Karen Elizabeth; Peel, Michael Robert

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 135 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9921859	A1	19990506	WO 1998-EP6357	19981008

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9911510 A1 19990517 AU 1999-11510 19981008

PRAI GB 1997-21437 19971010

WO 1998-EP6357 19981008

OS MARPAT 130:325139

GI



I

AB Title compds. [I; R1 = (substituted) Het, aryl, biaryl; R2-R4 = H, het, fused Het, aryl, aliphatyl, cyano, NO2, halo, OR5, SR5, SOR5, NR5R7, COR5, CO2R5, NR5COR5, CONR5R7, etc.; R5 = H, halo, (substituted) Het, aryl, aliphatyl, etc.; R7 = H, R5; Het = (R5 -substituted) acridinyl, benzimidazolyl, benzofuryl, carbazolyl, dithianyl, furyl, imidazolyl, morpholinyl, naphthyridinyl, oxadiazinyl, oxathiazolyl, pyrazolyl, pyridazinyl, quinoxalinyl, tetrazinyl, thiomorpholinyl, thiopyranyl, etc.], were prepd. Thus, 5-bromo-7-azaoxindole (prepn. given), 1-(3,5-dichlorophenyl)pyrrole-2-carboxaldehyde, and 4-methylmorpholine were refluxed in PhMe for 6 h to give 64% 5-bromo-3-[1-(3,5-dichlorophenyl)-1H-pyrrol-2-ylmethylidene]-1,3-dihydropyrrolo[2,3-b]pyridin-2-one. Several I inhibited raf kinase with IC50 < 1 .mu.M.

IT **223645-86-1P 223645-93-0P 223645-94-1P 223645-99-6P**

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of arylmethylideneazaoxindoles as protein kinase inhibitors)

RN 223645-86-1 CAPLUS

CN 2H-Pyrrolo[2,3-b]pyridin-2-one, 5-bromo-3-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 223645-93-0 CAPLUS
CN 2H-Pyrrolo[2,3-b]pyridin-2-one, 5-bromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 223645-94-1 CAPLUS
CN 2H-Pyrrolo[2,3-b]pyridin-2-one, 3-(2-furanylmethylene)-1,3-dihydro-5-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 223645-99-6 CAPLUS
CN 2H-Pyrrolo[2,3-b]pyridin-2-one,
3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-
5-(2-furanyl)-1,3-dihydro- (9CI) (CA INDEX NAME)



```
     FILE 'REGISTRY' ENTERED AT 10:11:20 ON 14 MAR 2000
L1              STRUCTURE UPLOADED
L2              QUE L1
L3           50 S L2
L4            1 S INDOLINE/CN

     FILE 'STNGUIDE' ENTERED AT 10:16:19 ON 14 MAR 2000

     FILE 'REGISTRY' ENTERED AT 10:18:10 ON 14 MAR 2000

     FILE 'STNGUIDE' ENTERED AT 10:18:11 ON 14 MAR 2000

     FILE 'REGISTRY' ENTERED AT 10:18:36 ON 14 MAR 2000
L5         41018 S NC4-NC5/ES
L6             1 S L2  SUB=L5 SAM
L7          1102 S L2 SSS FUL
L8             5 S L7 AND L5

     FILE 'CAPLUS' ENTERED AT 10:25:47 ON 14 MAR 2000
L9             2 S L8
L10          202 S L7

     FILE 'STNGUIDE' ENTERED AT 10:26:51 ON 14 MAR 2000
L11            0 S NC4-N2C4/ES

     FILE 'REGISTRY' ENTERED AT 10:30:48 ON 14 MAR 2000
L12         1406 S NC4-N2C4/ES
L13            0 S L7 AND L12
L14       414865 S NC4-C6/ES
L15         1097 S L14 AND L7
```